Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer

Jyoti Patel, MD
Published: Thursday, Sep 28, 2017



Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

There are a number of promising ongoing clinical trials combining chemotherapy and immunotherapy in lung cancer, says Patel.

In a phase III trial, the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed demonstrated a significantly higher response rate than chemotherapy alone, as well as an overall survival benefit. This combination led to the May 2017 FDA approval for patients as a frontline treatment.
 


Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

There are a number of promising ongoing clinical trials combining chemotherapy and immunotherapy in lung cancer, says Patel.

In a phase III trial, the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed demonstrated a significantly higher response rate than chemotherapy alone, as well as an overall survival benefit. This combination led to the May 2017 FDA approval for patients as a frontline treatment.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging Liquid Biopsies in Tumor Characterization for NSCLC TherapyJan 31, 20181.5
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Publication Bottom Border
Border Publication
x